- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00127907
Vasopressin and Epinephrine Versus Epinephrine Alone in Cardiac Arrest
October 16, 2007 updated by: Hospices Civils de Lyon
Comparison of Epinephrine Associated With Vasopressin vs Epinephrine Alone in the Treatment of Out-of-Hospital Cardiac Arrests
Recent studies have suggested that arginine-vasopressin could be more effective in the treatment of cardiac arrests.
The last published study did not outline obvious improvements in the prognosis of all cardiac arrests but pointed out a possible increased survival rate when arginine-vasopressin is associated with epinephrine.
The aim of this study is to compare the efficacy of two successive injections of epinephrine (1 mg) with two successive injections of epinephrine associated with arginine-vasopressin (40 UI) in out-of-hospital cardiac arrests occurring in adult patients.
The primary endpoint is the survival rate at hospital admission.
The inclusion period lasts 18 months and 2416 patients are planned to be enrolled.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment
2416
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Pierre Bénite, France, 69495
- Centre Hospitalier Lyon Sud
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Out-of-hospital medical cardiac arrest in adult patients.
Exclusion Criteria:
- Traumatic cardiac arrest
- Pregnancy
- Patients younger than 18 years old or older than 85 years old
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Survival at hospital admission
|
Secondary Outcome Measures
Outcome Measure |
---|
ROSC (Return of spontaneous circulation) Survival at : H24, Day 28, hospital discharge and one year Neurological status at H24 and hospital discharge.
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Pierre-Yves GUEUGNIAUD, MD, Hospices Civils de Lyon
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
May 1, 2004
Study Registration Dates
First Submitted
August 5, 2005
First Submitted That Met QC Criteria
August 5, 2005
First Posted (Estimate)
August 9, 2005
Study Record Updates
Last Update Posted (Estimate)
October 17, 2007
Last Update Submitted That Met QC Criteria
October 16, 2007
Last Verified
October 1, 2007
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Heart Diseases
- Cardiovascular Diseases
- Heart Arrest
- Out-of-Hospital Cardiac Arrest
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Natriuretic Agents
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Hemostatics
- Coagulants
- Adrenergic beta-Agonists
- Sympathomimetics
- Vasoconstrictor Agents
- Mydriatics
- Antidiuretic Agents
- Epinephrine
- Vasopressins
- Arginine Vasopressin
Other Study ID Numbers
- 2003.329
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiac Arrest
-
Italian Resuscitation CouncilUnknownOut-Of-Hospital Cardiac Arrest | In-hospital Cardiac ArrestItaly
-
Emergency Medical Services, Capital Region, DenmarkOdense University Hospital; TrygFonden, Denmark; Aalborg University HospitalUnknownOut-Of-Hospital Cardiac Arrest | Pediatric Disorder | Cardiopulmonary ArrestDenmark
-
Medical University of ViennaLudwig Boltzmann Institute Digital Health and Patient Safety; Emergency Medical...RecruitingCardiac Arrest, Out-Of-HospitalAustria
-
University Medical Centre MariborOHK Medical DevicesRecruiting"The Effect of the Use of an Autotransfusion Device on Hemodynamic Parameters During Resuscitation".Cardiac Arrest | Out of Hospital Cardiac ArrestSlovenia
-
National Taiwan University HospitalRecruitingOut-Of-Hospital Cardiac ArrestTaiwan
-
Far Eastern Memorial HospitalRecruitingOut-Of-Hospital Cardiac ArrestTaiwan
-
King's College LondonKing's College Hospital NHS Trust; London Ambulance Service NHS TrustNot yet recruiting
-
Wroclaw Medical UniversityWroclaw Emergency Medical ServicesRecruiting
-
Sunnybrook Health Sciences CentrePrescott-Russell Paramedic Service; Peterborough Paramedic Service; Bruce County... and other collaboratorsRecruiting
-
Emergency Medical Services, Capital Region, DenmarkTrygFonden, Denmark; Danish Heart Foundation; Zoll Medical CorporationRecruitingOut-Of-Hospital Cardiac ArrestDenmark
Clinical Trials on epinephrine (1 mg/1 mL)
-
Endo PharmaceuticalsCompletedAdhesive Capsulitis | Frozen ShoulderUnited States
-
Novo Nordisk A/SCompleted
-
AstraZenecaCompletedCardiovascular Disease | Healthy Male SubjectsUnited Kingdom
-
Kadmon Corporation, LLCQuotient SciencesCompletedHealthy VolunteersUnited Kingdom
-
Hospital Universitario Ramon y CajalTerminated
-
Suzhou Connect Biopharmaceuticals, Ltd.CompletedHealthy Adult SubjectsChina
-
GOIZETBioMarin PharmaceuticalRecruiting
-
Aevi Genomic Medicine, LLC, a Cerecor companyCompletedAttention Deficit Disorder With HyperactivityUnited States
-
Sintetica SACross Research S.A.CompletedPain, PostoperativeSwitzerland